0000000000330865

AUTHOR

D. Gonzalez De Castro

showing 2 related works from this author

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

2015

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

MaleOncologyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLET-7 MICRORNA-BINDINGCetuximabmedicine.disease_causeCOLORECTAL-CANCER3'-UNTRANSLATED REGION0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRectal cancerNeoadjuvant therapySingle-nucleotide polymorphism0303 health sciencesCetuximabCOLON-CANCERHazard ratioCAPOX RegimenChemoradiotherapyHematologysingle-nucleotide polymorphismMiddle AgedCombined Modality TherapyNeoadjuvant TherapyBINDING SITE POLYMORPHISM3. Good healthOxaliplatinLet-7Oncology030220 oncology & carcinogenesis5-FLUOROURACIL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleKRASLife Sciences & Biomedicinemedicine.drugAdultGenetic Markersmedicine.medical_specialtyGenotypeLCS-6 KRAS variantPolymorphism Single NucleotideDisease-Free SurvivalCLINICAL-TRIALProto-Oncogene Proteins p21(ras)03 medical and health sciencesSDG 3 - Good Health and Well-beinglet-7Internal medicineGastrointestinal TumorsBiomarkers TumorKRASmedicineHumansOncology & CarcinogenesisProgression-free survivalrectal cancerneoplasmsCapecitabineAged030304 developmental biologyCancer och onkologiScience & TechnologyRectal Neoplasmsbusiness.industryOriginal Articlesmedicine.diseasedigestive system diseasesMicroRNAsCancer and Oncologybusiness1112 Oncology And CarcinogenesisChemoradiotherapyRASAnnals of Oncology
researchProduct

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and che…

2013

HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT +/- cetuximab in the EXPERT-C trial. Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric…

OncologyAdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerReceptor ErbB-2medicine.medical_treatmentCetuximabAdenocarcinomamedicine.disease_causeAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind Methodskin and connective tissue diseasesneoplasmsNeoadjuvant therapyCapecitabineAgedProportional Hazards ModelsRetrospective StudiesCetuximabbusiness.industryRectal NeoplasmsCancerCAPOX RegimenHematologyChemoradiotherapyMiddle Agedmedicine.diseaseNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFemaleKRASFluorouracilbusinessChemoradiotherapymedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct